Can phylogenetic type predict resistance development?

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 778-787

  Nazir, Humera ^a,b   Cao, Sha ^a   Hasan, Fariha ^b   Hughes, Diarmaid ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b QUAID I AZAM UNIVERSITY   (Pakistan)

Author keywords

Antibiotic resistance; ESBLs; Fluoroquinolones

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; BACTERIAL PROTEIN; CEFALOTIN; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXYCYCLINE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; MEROPENEM; NALIDIXIC ACID; NITROFURANTOIN; PROTEIN PARC; QEPA PROTEIN; QNRA PROTEIN; QNRB PROTEIN; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CITROBACTER; ENTEROBACTER; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHYLOGENY; PROTEUS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS SAPROPHYTICUS; STREPTOCOCCUS; URINARY TRACT INFECTION;

ADULT; AMINO ACID SUBSTITUTION; BACTERIAL TYPING TECHNIQUES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; GENOTYPE; HUMANS; MALE; MOLECULAR TYPING; MUTATION, MISSENSE; PAKISTAN; PHYLOGENY; URINARY TRACT INFECTIONS;

EID: 79952805422     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq505     Document Type: Article

References (52)

1. Wagenlehner FM, Weidner W, Naber KG. An update on uncomplicated urinary tract infections in women. Curr Opin Urol 2009; 19: 368-74.
2. Kahlmeter G. The ECO.SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother 2000; 46 Suppl 1: 15-22; discussion 63-5.
3. EARSS. European Antimicrobial Resistance Surveillance System Annual Report 2008. www.earss.rivm.nl (2 December 2010, date last accessed).
4. Wagenlehner FM, Naber KG. Treatment of bacterial urinary tract infections: presence and future. Eur Urol 2006; 49: 235-44.
5. Deuster S, Roten I, Muehlebach S. Implementation of treatment guidelines to support judicious use of antibiotic therapy. J Clin Pharm Ther 2010; 35: 71-8.
6. Johnson L, Sabel A, Burman WJ et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008; 121: 876-84.
7. Caterino JM, Weed SG, Espinola JA et al. National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996-2005. Acad Emerg Med 2009; 16: 500-7.
8. Kashanian J, Hakimian P, Blute M Jr et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int 2008; 102: 1634-7.
9. Olson RP, Harrell LJ, Kaye KS. Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. Antimicrob Agents Chemother 2009; 53: 1285-6.
10. Yilmaz N, Agus N, Yurtsever SG et al. Prevalence and antimicrobial susceptibility of Escherichia coli in outpatient urinary isolates in Izmir, Turkey. Med Sci Monit 2009; 15: PI61-5.
11. Kothari A, Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev Ctries 2008; 2: 354-8.
12. Kurtaran B, Candevir A, Tasova Y et al. Antibiotic resistance in community-acquired urinary tract infections: prevalence and risk factors. Med Sci Monit 2010; 16: CR246-51.
13. Arredondo-Garcia JL, Amabile-Cuevas CF. High resistance prevalence towards ampicillin, co-trimoxazole and ciprofloxacin, among uropathogenic Escherichia coli isolates in Mexico City. J Infect Dev Ctries 2008; 2: 350-3.
14. Guajardo-Lara CE, Gonzalez-Martinez PM, Ayala-Gaytan JJ. [Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections. What antimicrobial to use?]. Salud Publica Mex 2009; 51: 155-9.
15. Yengkokpam C, Ingudam D, Yengkokpam IS et al. Antibiotic susceptibility pattern of urinary isolates in Imphal (Manipur), India. Nepal Med Coll J 2007; 9: 170-2.
16. Chatterjee B, Kulathinal S, Bhargava A et al. Anti-microbial resistance stratified by risk factor among Escherichia coli strains isolated from the urinary tract at a rural clinic in Central India. Indian J Med Microbiol 2009; 27: 329-34.
17. Kamat U, Ferreira A, Savio R et al. Antimicrobial resistance among nosocomial isolates in a teaching hospital in Goa. Indian J Community Med 2008; 33: 89-92.
18. Holt J. Bergey's Manual of Determinative Bacteriology. Baltimore: Williams & Wilkins, 1994.
19. Bauer AW, Kirby WM, Sherris JC et al. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45: 493-6.
20. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 1.1, April 2010. www.eucast.org (2 December 2010, date last accessed).
21. Jorgensen JH, McElmeel ML, Fulcher LC et al. Detection of CTX-M-type extended-spectrum b-lactamase (ESBLs) by testing with MicroScan overnight and ESBL confirmation panels. J Clin Microbiol 2010; 48: 120-3.
22. Komp Lindgren P, Karlsson Å, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222-32.
23. Jacoby GA, Gacharna N, Black TA et al. Temporal appearance of plasmid-mediated quinolone resistance genes. Antimicrob Agents Chemother 2009; 53: 1665-6.
24. Kim HB, Park CH, Kim CJ et al. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother 2009; 53: 639-45.
25. Yoshida H, Bogaki M, Nakamura M et al. Quinolone resistancedetermining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990; 34: 1271-2.
26. Marcusson LL, Frimodt-Moller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009; 5: e1000541.
27. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996; 40: 879-85.
28. Kumagai Y, Kato JI, Hoshino K et al. Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother 1996; 40: 710-14.
29. Komp Lindgren P, Marcusson LL, Sandvang D et al. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 2005; 49: 2343-51.
30. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 2005; 25: 358-73.
31. Kawamura-Sato K, Yoshida R, Shibayama K et al. Virulence genes, quinolone and fluoroquinolone resistance, and phylogenetic background of uropathogenic Escherichia coli strains isolated in Japan. Jpn J Infect Dis 2010; 63: 113-5.
32. Takahashi A, Muratani T, Yasuda M et al. Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns. J Clin Microbiol 2009; 47: 791-5.
33. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66: 4555-8.
34. Robicsek A, Strahilevitz J, Jacoby GA et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006; 12: 83-8.
35. Tolmasky ME, Roberts M, Woloj M et al. Molecular cloning of amikacin resistance determinants from a Klebsiella pneumoniae plasmid. Antimicrob Agents Chemother 1986; 30: 315-20.
36. Woloj M, Tolmasky ME, Roberts MC et al. Plasmid-encoded amikacin resistance in multiresistant strains of Klebsiella pneumoniae isolated from neonates with meningitis. Antimicrob Agents Chemother 1986; 29: 315-9.
37. Perichon B, Courvalin P, Galimand M. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother 2007; 51: 2464-9.
38. Yamane K, Wachino J, Suzuki S et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother 2007; 51: 3354-60.
39. Strahilevitz J, Jacoby GA, Hooper DC et al. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009; 22: 664-89.
40. Örlén H, Hughes D. Weak mutators can drive the evolution of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2006; 50: 3454-6.
41. Mao EF, Lane L, Lee J et al. Proliferation of mutators in a cell population. J Bacteriol 1997; 179: 417-22.
42. Kanamaru S, Kurazono H, Nakano M et al. Subtyping of uropathogenic Escherichia coli according to the pathogenicity island encoding uropathogenic-specific protein: comparison with phylogenetic groups. Int J Urol 2006; 13: 754-60.
43. Bjorkman J, Hughes D, Andersson DI. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 1998; 95: 3949-53.
44. Nagaev I, Bjorkman J, Andersson DI et al. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 2001; 40: 433-9.
45. Schrag SJ, Perrot V. Reducing antibiotic resistance. Nature 1996; 381: 120-1.
46. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-71.
47. Hughes D. Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat Rev Genet 2003; 4: 432-41.
48. Heisig P, Tschorny R. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemother 1994; 38: 1284-91.
49. Johnson JR, Delavari P, Kuskowski M et al. Phylogenetic distribution of extraintestinal virulence-associated traits in Escherichia coli. J Infect Dis 2001; 183: 78-88.
50. Picard B, Garcia JS, Gouriou S et al. The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect Immun 1999; 67: 546-53.
51. Tartof SY, Solberg OD, Riley LW. Genotypic analyses of uropathogenic Escherichia coli based on fimH single nucleotide polymorphisms (SNPs). J Med Microbiol 2007; 56: 1363-9.
52. Mohapatra BR, Broersma K, Mazumder A. Comparison of five rep-PCR genomic fingerprinting methods for differentiation of fecal Escherichia coli from humans, poultry and wild birds. FEMS Microbiol Lett 2007; 277: 98-106.